SecBot SecBot
6-K ·Filed Jul 21, 2026

TLX

Telix Pharmaceuticals Ltd
BULLISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001628280-26-048922
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong Q2 beat and reaffirmed upper-end guidance confirm commercial momentum. The Regeneron partnership and convertible bond refinancing strengthen the balance sheet and pipeline optionality. Key catalysts to watch: Pixclara PDUFA date September 11, 2026, and Zircaix BLA resubmission timing.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

TLX drug pipeline →

TLX591-Tx

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
Next catalyst
None dated

What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+60
Entry
$10.92
T+0 close · Jul 21, 2026 · via day close
Latest settled
0.00%
T+60 · $10.92
Vs SPY
−3.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $10.92entry
  2. T+1 · 4mo ago −5.49%α −5.38% · $10.32
  3. T+5 · 4mo ago −8.61%α −7.38% · $9.98
  4. T+20 · 3mo ago +8.79%α +6.23% · $11.88
  5. T+60 · 5w ago 0.00%α −3.97% · $10.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY). FY2026 revenue guidance is tracking at the upper end of US$950M-$970M, with total 2026 revenue and other income expected to exceed US$1B including a US$40M non-refundable payment from Regeneron. The company also announced a strategic collaboration with Regeneron, a US$600M convertible bond refinancing extending maturities, and FDA alignment to advance the ProstACT Phase 3 trial of TLX591-Tx.

Key Facts

  • Q2 2026 group revenue of US$247M, up 21% YoY and 7% QoQ
  • Precision Medicine revenue of US$202M, up 30% YoY
  • FY2026 revenue guidance tracking at upper end of US$950M-$970M, plus US$40M Regeneron payment
  • R&D expenditure guidance updated to US$230M-$270M
  • Entered strategic collaboration with Regeneron to develop next-gen radiopharmaceutical therapies
  • Completed US$600M convertible bond refinancing, extending maturities to 2031
  • FDA alignment on ProstACT Global Phase 3 trial of TLX591-Tx to advance to Part 2 in the US
  • BiPASS Phase 3 study of Illuccix and Gozellix enrolled 338 patients

Financial Impact

Revenue growth of 21% YoY to US$247M in Q2, with FY2026 guidance implying >US$1B total revenue and other income

revenueguidanceR&D spend

Risk Factors

  • R&D expenditure guidance increased to US$230M-$270M, potentially pressuring near-term profitability
  • Pipeline execution risk for late-stage trials (TLX591-Tx, TLX101-Tx, TLX250-Tx)
  • Regulatory risk for Pixclara and Zircaix approvals
  • Convertible bond issuance adds debt, though extends maturities

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-048922
Document: telix-6kforq22026tradingup.htm0001628280-26-048922
Document: 0001628280-26-048922-index-headers.html0001628280-26-048922
Document: 0001628280-26-048922-index.html0001628280-26-048922
Document: 0001628280-26-048922.txt0001628280-26-048922

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (9h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 21, 2026